VRDN FY 2018 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+109.5% YoY

Gross Profit

-$22M-262.8% margin

Operating Income

-$33M-394.5% margin

Net Income

-$33M-390.0% margin

EPS (Diluted)

$-16.57

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$66M

Total Liabilities

$15M

Stockholders' Equity

$51M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$4M	+109.5%
Gross Profit	-$22M	-$16M	-41.1%
Operating Income	-$33M	-$27M	-24.7%
Net Income	-$33M	-$27M	-23.4%